WOOJUNG BIO Statistics
Total Valuation
WOOJUNG BIO has a market cap or net worth of KRW 30.19 billion. The enterprise value is 78.65 billion.
| Market Cap | 30.19B | 
| Enterprise Value | 78.65B | 
Important Dates
| Earnings Date | n/a | 
| Ex-Dividend Date | n/a | 
Share Statistics
WOOJUNG BIO has 16.83 million shares outstanding. The number of shares has increased by 22.66% in one year.
| Current Share Class | 16.83M | 
| Shares Outstanding | 16.83M | 
| Shares Change (YoY) | +22.66% | 
| Shares Change (QoQ) | n/a | 
| Owned by Insiders (%) | 33.61% | 
| Owned by Institutions (%) | 3.65% | 
| Float | 10.22M | 
Valuation Ratios
| PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 0.83 | 
| PB Ratio | 1.20 | 
| P/TBV Ratio | 1.24 | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.39, with an EV/FCF ratio of -22.97.
| EV / Earnings | -19.00 | 
| EV / Sales | 2.15 | 
| EV / EBITDA | 30.39 | 
| EV / EBIT | n/a | 
| EV / FCF | -22.97 | 
Financial Position
The company has a current ratio of 0.56, with a Debt / Equity ratio of 2.06.
| Current Ratio | 0.56 | 
| Quick Ratio | 0.21 | 
| Debt / Equity | 2.06 | 
| Debt / EBITDA | 20.06 | 
| Debt / FCF | -15.17 | 
| Interest Coverage | -0.46 | 
Financial Efficiency
Return on equity (ROE) is -16.34% and return on invested capital (ROIC) is -1.13%.
| Return on Equity (ROE) | -16.34% | 
| Return on Assets (ROA) | -0.95% | 
| Return on Invested Capital (ROIC) | -1.13% | 
| Return on Capital Employed (ROCE) | -2.35% | 
| Revenue Per Employee | n/a | 
| Profits Per Employee | n/a | 
| Employee Count | n/a | 
| Asset Turnover | 0.40 | 
| Inventory Turnover | 4.39 | 
Taxes
| Income Tax | n/a | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
The stock price has decreased by -12.14% in the last 52 weeks. The beta is 0.85, so WOOJUNG BIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 | 
| 52-Week Price Change | -12.14% | 
| 50-Day Moving Average | 1,739.02 | 
| 200-Day Moving Average | 1,674.03 | 
| Relative Strength Index (RSI) | 55.54 | 
| Average Volume (20 Days) | 1,291,297 | 
Short Selling Information
| Short Interest | n/a | 
| Short Previous Month | n/a | 
| Short % of Shares Out | n/a | 
| Short % of Float | n/a | 
| Short Ratio (days to cover) | n/a | 
Income Statement
In the last 12 months, WOOJUNG BIO had revenue of KRW 36.60 billion and -4.14 billion in losses. Loss per share was -308.29.
| Revenue | 36.60B | 
| Gross Profit | 10.81B | 
| Operating Income | -1.38B | 
| Pretax Income | -4.14B | 
| Net Income | -4.14B | 
| EBITDA | 2.59B | 
| EBIT | -1.38B | 
| Loss Per Share | -308.29 | 
Balance Sheet
The company has 3.51 billion in cash and 51.96 billion in debt, giving a net cash position of -48.45 billion or -2,879.14 per share.
| Cash & Cash Equivalents | 3.51B | 
| Total Debt | 51.96B | 
| Net Cash | -48.45B | 
| Net Cash Per Share | -2,879.14 | 
| Equity (Book Value) | 25.19B | 
| Book Value Per Share | 1,511.20 | 
| Working Capital | -14.18B | 
Cash Flow
In the last 12 months, operating cash flow was -2.87 billion and capital expenditures -552.97 million, giving a free cash flow of -3.42 billion.
| Operating Cash Flow | -2.87B | 
| Capital Expenditures | -552.97M | 
| Free Cash Flow | -3.42B | 
| FCF Per Share | -203.48 | 
Margins
Gross margin is 29.54%, with operating and profit margins of -3.77% and -11.31%.
| Gross Margin | 29.54% | 
| Operating Margin | -3.77% | 
| Pretax Margin | -11.31% | 
| Profit Margin | -11.31% | 
| EBITDA Margin | 7.08% | 
| EBIT Margin | -3.77% | 
| FCF Margin | n/a | 
Dividends & Yields
WOOJUNG BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -22.66% | 
| Shareholder Yield | -22.66% | 
| Earnings Yield | -13.71% | 
| FCF Yield | -11.34% | 
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
The last stock split was on July 30, 2019. It was a forward split with a ratio of 2.
| Last Split Date | Jul 30, 2019 | 
| Split Type | Forward | 
| Split Ratio | 2 | 
Scores
WOOJUNG BIO has an Altman Z-Score of -0.02 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.02 | 
| Piotroski F-Score | 3 |